ASH 2022 | Insights into the REVEAL trial: the efficacy of ruxolitinib for the treatment of patients with PV
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, summarizes the structure and findings of the REVEAL trial (NCT02252159), which is the largest prospective observational study of patients with polycythemia vera (PV) conducted to date. Dr Gerds explains that the results from this trial combined with real-world data (RWD) validate the efficacy of ruxolitinib in improving the outcomes of patients with PV. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So we also presented at this year’s ASH annual meeting, a poster from the REVEAL study. So the REVEAL is the largest prospective observational study of patients with polycythemia vera ever conducted. Patients were enrolled. 2,500 patients were enrolled in this study, in fact, and were monitored for a minimum of 36 months. The average duration of observation though was over six years. And from this database we can pull out all kinds of wonderful studies looking at lots of different aspects of polycythemia vera...
So we also presented at this year’s ASH annual meeting, a poster from the REVEAL study. So the REVEAL is the largest prospective observational study of patients with polycythemia vera ever conducted. Patients were enrolled. 2,500 patients were enrolled in this study, in fact, and were monitored for a minimum of 36 months. The average duration of observation though was over six years. And from this database we can pull out all kinds of wonderful studies looking at lots of different aspects of polycythemia vera. So last year we reported that increasing white counts and increasing platelet counts were associated with thrombosis. Most importantly, increasing white counts, especially when the hematocrit is under good control.
This year we took a look at the same REVEAL database and started looking at, well, if you can use another medication to try to control these counts, do patients still do well? And particularly with an interest in ruxolitinib and trying to develop real-world, if you will, evidence for the use of ruxolitinib in this setting. And the bottom line from this abstract was that the use of ruxolitinib in this prospective study, which is more of a real-world study, again, those results with ruxolitinib do definitely reflect what was seen in the clinical trials. So the real-world application of the clinical trials seems to impart the same effect that the clinical trials did, which is incredibly positive.
Read more...
Disclosures
Kratos Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Imago BioSciences: Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Accurate Pharmaceuticals: Research Funding; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Morphosys/Constellation: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; PharmaEssentia: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
